A single-arm, prospective, Phase II clinical study of surufatinib in combination with tislelizumab in advanced colorectal cancer after third-line treatment failure
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
Interventions: Test group:Surufatinib+tislelizumab Primary outcome(s): Progression-free survival Study Design: Single arm
创建时间：
2022-05-15
